Navigation Links
Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
Date:3/6/2009

CORONA, Calif., March 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Elan Corporation, Plc on outstanding patent litigation related to Watson's generic version of Naprelan(R) (naproxen sodium) tablets.

Under the terms of the agreement, Watson will pay Elan $18 million in full settlement of all disputes related to Watson's development, manufacturing, marketing and sale of its naproxen sodium product. Watson also has agreed not to market or sell its naproxen sodium product until the expiration or final finding of invalidity or unenforceability of U.S. Patent No. 5,637,320. Other details concerning the settlement have not been disclosed.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceutical's Web site at http://www.watson.com.

Watson's Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, risks that resolution of patent infringement litigation through settlement could result in investigations or actions by private parties or government authorities, including the U.S. Department of Justice and /or the Federal Trade Commission; the difficulty of predicting the timing or outcome of litigation related to patent infringement; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

Naprelan(R) is a registered trademark of Elan Corporation, Plc

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
2. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
3. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
4. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
5. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
6. U.S. Workers Taking Steps to Lower Medical Costs, Watson Wyatt Survey Finds
7. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
8. Driving Consumer Engagement Is Focus of Address by Healthfitness Chief Medical Officer at Watson Wyatt Health Care Solutions Event
9. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
10. Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr
11. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... to help you brush more effectively even on the go. Their electric toothbrushes ... gingivitis and gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology ...
(Date:9/22/2017)... ... September 22, 2017 , ... The freshly released app Smart ... to Smart Mart, customers can now order vegetable, fruit, snacks, dairy, or any ... find clothing at discounted prices. Apart from this, Smart Mart has emphasized upon ...
(Date:9/21/2017)... ... September 21, 2017 , ... With ProSlideshow Portrait from Pixel Film Studios ... Users can select from up to two layers of subject matter along with fully ... all within Final Cut Pro X. , With ProSlideshow Portrait each user ...
(Date:9/21/2017)... Chicago, IL (PRWEB) , ... September 21, 2017 , ... ... set to run from September 11 to the end of November. , The Chicago, ... out to their community and teach them about the ease of taking their personal ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... INDIANAPOLIS , Sept. 7, 2017  Eli ... today announced actions to streamline operations to more ... to improve its cost structure. Global workforce reductions, ... program, are expected to impact approximately 3,500 positions. ... the company expects annualized savings of approximately $500 ...
(Date:9/7/2017)... , Sept. 7, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Healthcare Conference at the Grand Hyatt hotel in New ... 2017 at 11:40 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
Breaking Medicine Technology: